The FDA last week approved Rigel Pharmaceuticals’ Rezlidhia for the treatment of relapsed or refractory acute myeloid leukemia (AML) with the IDH1 mutation in adult patients. The drugmaker in August paid just $2 million to Forma Therapeutics for Rezlidhia’s exclusive licensing rights. The approval means Rezlidhia will go head-to-head with Servier’s Tibsovo, which scored a nod for IDH1-mutated AML in May. For the treatment of AML, Tibsovo currently holds covered or better status for 96% of all insured lives under the pharmacy benefit. About 29% of insured lives have preferred access to Tibsovo, largely with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 12/5/22